Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP2 | O95551 | 1/20 | 0.39 |
| ▸ | PDE1B | Q01064 | 4/20 | 0.38 |
| ▸ | PDE1C | Q14123 | 3/20 | 0.37 |
| ▸ | PDE1A | P54750 | 2/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | OGFRL1 | Q5TC84 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.36 |
| ▸ | AADAT | Q8N5Z0 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
| ▸ | AKT1 | P31749 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2963777 | 0.93 | OGFRL1 (0.38) | TDP2PDE1BPDE1CPDE1AHTT | |
| SCHEMBL12225747 | 0.89 | ADORA2A (0.41) | OGFRL1L3MBTL1ALDH1A1MAPT | |
| SCHEMBL6093597 | 0.80 | HTT (0.52) | HTTL3MBTL1KDM4EALDH1A1AKT1 | |
| SCHEMBL2961577 | 0.79 | OGFRL1 (0.38) | HTTOGFRL1L3MBTL1KDM4EALDH1A1 | |
| SCHEMBL2963347 | 0.77 | OGFRL1 (0.36) | HTTOGFRL1L3MBTL1KDM4EALDH1A1 | |
| SCHEMBL22079303 | 0.77 | NPSR1 (0.39) | ALDH1A1 | |
| SCHEMBL20386876 | 0.75 | KMT2A (0.43) | HTTL3MBTL1ALDH1A1MAPT | |
| SCHEMBL22079305 | 0.75 | ADORA2A (0.40) | ALDH1A1PDE4B | |
| SCHEMBL20379042 | 0.73 | PDE4A (0.45) | HTTL3MBTL1ALDH1A1MAPT | |
| SCHEMBL13691642 | 0.73 | OGFRL1 (0.36) | HTTOGFRL1L3MBTL1KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7763630-B2 | pyrimidinone compounds such as N-(4-Fluorobenzyl)-5-hydroxy-1-methyl-6-oxo-2-(tetrahydrofuran-3-yl)-1,6-dihydropyrimidine-4-carboxamide, used for treating human immunodeficiency virus (HIV) and acquired immune deficiency syndrome (AIDS) | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-07-27 | — | — | US | disclosed |
| US-7763630-B2 | pyrimidinone compounds such as N-(4-Fluorobenzyl)-5-hydroxy-1-methyl-6-oxo-2-(tetrahydrofuran-3-yl)-1,6-dihydropyrimidine-4-carboxamide, used for treating human immunodeficiency virus (HIV) and acquired immune deficiency syndrome (AIDS) | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-07-27 | — | — | US | disclosed |
| US-7763630-B2 | pyrimidinone compounds such as N-(4-Fluorobenzyl)-5-hydroxy-1-methyl-6-oxo-2-(tetrahydrofuran-3-yl)-1,6-dihydropyrimidine-4-carboxamide, used for treating human immunodeficiency virus (HIV) and acquired immune deficiency syndrome (AIDS) | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-07-27 | — | — | US | disclosed |
| WO-2008154246-A1 | HIV INTEGRASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-12-18 | — | — | WO | disclosed |
| WO-2008154246-A1 | HIV INTEGRASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-12-18 | — | — | WO | disclosed |
| US-20080306051-A1 | HIV Integrase Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2008-12-11 | — | — | US | disclosed |
| US-20080306051-A1 | HIV Integrase Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2008-12-11 | — | — | US | disclosed |
| US-20080306051-A1 | HIV Integrase Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2008-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306051-A1 | HIV Integrase Inhibitors | TYMP, IMPDH1, UNG | TDP2 158/4885PDE1B 2998/4885PDE1C 3097/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.